A Phase 1/2 interventional study of TQB3909 Tablets + Azacitidine in Myeloid Malignancy, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of one of the following diseases:
Exclusion Criteria:
Comorbidities and Medical History:
Tumor-related Symptoms and Treatment:
Study Treatment-related:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQB3909 Tablets administered once-daily. 28 days as a treatment cycle.
Drug: TQB3909 Tablets + Azacitidine
Drug pages: Bcl-2 Inhibitor TQB3909 · Azacitidine
TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue
Incidence and severity of adverse events (AE) and serious adverse events (SAE), abnormal laboratory parameters
Any adverse medical event that occurred from the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy (whichever occurs first)
Time frame: Up to 24 weeks
Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) Rate
Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) Rate
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Investigator-Assessed Objective Response Rate (ORR)
Proportion of subjects with best response as Complete Remission (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Morphologic Leukemia-Free State (MLFS), or Partial Remission (PR)
Time frame: Up to 4 weeks
Myelodysplastic Syndromes: Investigator-Assessed Objective Response Rate (ORR)
Proportion of subjects with best response as CR, Morphological Complete Remission (mCR), or PR
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Complete Remission + Complete Remission with Incomplete Hematologic Recovery (CR+CRi) Rate
Proportion of subjects with best response as CR+CRi. CRi refers to meeting all CR criteria except for residual neutrophil count decrease (ANC \< 1.0 × 109/L) or platelet count decrease (PLT \< 100 × 109/L).
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) Rate
Proportion of subjects with best response as CR
Time frame: Up to 4 weeks
Acute Myeloid Leukemia and Myelodysplastic Syndromes: Complete Remission (CR) Rate
Proportion of subjects with best response as CR
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Duration of Remission (DOR)
For all subjects with best response as CR, CRi, MLFS, or PR, the time from the first date of achieving remission to the first recorded date of disease progression, relapse, or death (whichever occurs first).
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Duration of CR + CRh (DOCR+CRh)
For all subjects with best response as CR or CRh, the time from the first date of achieving CR or CRh to the first recorded date of relapse or death (whichever occurs first).
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Duration of Complete Remission (DOCR)
For all subjects with best response as CR, the time from the first date of achieving CR to the first recorded date of relapse or death (whichever occurs first).
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Time to First Complete Remission (TTCR)
For all subjects with best response as CR or CRh, the time from the first date of medication to the first date of CR or CRh.
Time frame: Up to 4 weeks
Acute Myeloid Leukemia: Time to First Complete Remission (TTCR)
For subjects with best response as CR, the time from the first date of medication to the first date of CR.
Time frame: Up to 4 weeks
Acute Myeloid Leukemia and Myelodysplastic Syndromes: Event-Free Survival (EFS)
Defined as the duration from the first dose of medication to treatment failure, relapse after CR or CRi, or death due to any cause (whichever occurs first). Treatment failure is defined as not achieving CR or CRi at any assessment time during treatment. Subjects with treatment failure will be considered to have an EFS event on the first day after the first dose. For subjects with CR or CRi, the event time will be the time of disease relapse or death (whichever occurs first).
Time frame: Up to 4 weeks
Acute Myeloid Leukemia and Myelodysplastic Syndromes: Overall Survival (OS)
The time from the first dose of medication to the date of death due to any cause.
Time frame: Up to 60 weeks
Myelodysplastic Syndromes: Hematologic Improvement (HI) Rate
Proportion of subjects meeting Hematologic Improvement (HI) criteria, including Hematologic Improvement - Erythrocyte (HI-E), Hematologic Improvement - Platelet (HI-P), and Hematologic Improvement - Neutrophil (HI-N).
Time frame: Up to 4 weeks
Myelodysplastic Syndromes: Transfusion Independence Rate
The proportion of subjects who did not require transfusions for at least 56 days after baseline, relative to the number of baseline transfusion-dependent and transfusion-independent subjects.
Time frame: Up to 8 weeks
Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bcl-2 Inhibitor TQB3909 · Azacitidine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →